Recent developments in health include EU approval of Novo's Wegovy for obesity-related heart conditions, the US FDA's nod for ...

Researchers from the Chinese Academy of Medical Sciences reported the discovery of the 1,2,4-oxadiazole derivative FO-4-15 for the treatment of Alzheimer’s disease (AD).

Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

WITH all the buzz around the so-called ‘miracle’ weight-loss jabs Ozempic, you could easily mistake it for a cure for all. Although created to help manage type 2 diabetes the ...

Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...

Among other movers, Novo Nordisk advanced 0.5% after the European Medicines Agency backed the use of the Danish drugmaker’s ...

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.